Screener
Sutro Biopharma STRO Balance Sheet Statement
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| $46.85M-28.9% | $54.34M-15.1% | $73.68M-30.6% | $58.13M-69.5% | $65.93M-62.2% | ||
| $95.33M-6.2% | $110.01M-22.0% | $128.88M-9.7% | $83.3M-34.2% | $101.67M-52.4% | ||
| $12.82M+227% | $5.8M-27.5% | $12.48M-7.9% | $3.98M-53.8% | $3.92M-41.1% | ||
| $159.5M-12.4% | $175.65M-24.2% | $220.97M-23.1% | $150.93M-56.0% | $182.11M-55.1% | ||
| $7.13M-46.6% | $8.36M-44.2% | $9.36M-44.3% | $10.65M-41.5% | $13.35M-29.7% | ||
| $176.65M-15.7% | $194.46M-25.9% | $241.99M-24.7% | $173.83M-55.1% | $209.66M-53.6% | ||
| $2.84M-59.6% | $3.36M-22.1% | $5.49M-32.9% | $7.57M-27.8% | $7.03M+13.2% | ||
| $8.27M-7.9% | $6.46M-46.0% | $9.4M-86.4% | $10.56M-84.9% | $8.98M-87.6% | ||
| $54.31M-24.5% | $52.9M-28.8% | $70.81M-46.8% | $75.13M-43.0% | $71.9M-45.2% | ||
| $309.18M+4.1% | $297.78M+1.1% | $308.88M-11.0% | $306.28M-10.6% | $296.93M-12.8% | ||
| $17K-80.0% | $17K-80.0% | $17K-79.8% | $9K+12.5% | $85K+3.7% | ||
| -$1.09B-16.7% | -$1.05B-20.7% | -$1.02B-17.8% | -$977.96M-24.3% | -$931.19M-30.3% | ||
| -$132.54M-51.9% | -$103.32M-222% | -$66.89M-159% | -$132.45M-397% | -$87.27M-178% | ||
| $176.65M-15.7% | $194.46M-25.9% | $241.99M-24.7% | $173.83M-55.1% | $209.66M-53.6% |
FAQ
- What are Sutro Biopharma's total assets?
- Sutro Biopharma (STRO) holds $176.6M in total assets, down 15.7% year over year.
- How much debt does Sutro Biopharma have?
- Sutro Biopharma carries $9.7M in total debt against -$132.5M of shareholders' equity, a debt-to-equity ratio of 0.52.
- How much cash does Sutro Biopharma have?
- Sutro Biopharma holds $46.9M in cash and equivalents.
- Can Sutro Biopharma cover its short-term obligations?
- Its current ratio is 2.94 — current assets exceed current liabilities.
- Where does Sutro Biopharma's balance sheet data come from?
- Every line is extracted from Sutro Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
